National basic drug catalogue 2018 officially implemented anticancer drugs ushered in good news

[policies and regulations of China Pharmaceutical network] anticancer drugs are life-saving drugs! On November 1, the catalogue of national essential drugs (2018 Edition) was officially implemented It is reported that there are 12 new anticancer drugs in the adjusted base drug list The implementation of the catalogue will once again bring benefits to the anticancer drug market Recently, a well-known domestic host died of cancer, which broke the wechat circle of friends While lamenting, we can't help worrying that cancer seems to be getting younger and younger In order to ensure that cancer patients have medicine to be treated and the medicine can be used, new policies have been introduced in China It is reported that 187 kinds of drugs were transferred in and 22 kinds were transferred out The total number of varieties reached 685, including 417 kinds of Western medicine and 268 kinds of Chinese patent medicine The "selection" of various drugs attracted people's attention Among them, 12 kinds of anticancer drugs have been added into the list of basic drugs, making 38 kinds of anticancer drugs, among which there are many innovative drugs such as small molecule targeted drugs, which bring good news to cancer patients Cancer drugs are life-saving It is understood that since this year, in addition to the introduction of new anticancer drugs into the base drug catalog, favorable policies have been successively issued, such as zero tariff for anticancer drugs, centralized procurement through government negotiations, inclusion in the medical insurance reimbursement catalog, and acceleration of the import and listing of innovative drugs The release of these policies has brought many benefits to cancer patients Today, the average price reduction of cancer drugs is 56.7% At present, there are more than 3 million new cancer cases every year in China, many of them are facing the dilemma of being unable to afford medicine Therefore, it is very important to promote the price reduction of anticancer drugs and strengthen the innovation and research of anticancer drugs in China I learned that in recent years, the speed of new drug approval in China has been greatly accelerated "In the past, it took several years for an original new drug to be applied, approved and put on the market In May this year, multiple sclerosis was included in China's list of rare diseases Under the encouragement of national policies, a certain imported drug was approved in China on July 18, and was delivered in Beijing, Shanghai and Guangzhou in the middle of September In just 58 days, the speed of listing of rare disease drugs in China was set " Experts said that improving the research and development capacity of anti-cancer drugs in China is the fundamental strategy to reduce the cost of anti-cancer drugs and reduce the dependence on imported anti-cancer drugs Due to the high risk of research and development of innovative drugs, most domestic pharmaceutical companies were reluctant to make innovative drugs in the past, and most tumor drugs were monopolized by foreign enterprises in the past However, under the encouragement and support of various policies, through continuous R & D investment and technological innovation, national pharmaceutical enterprises have also launched their own original new tumor drugs At present, China is speeding up the research and development of innovative drugs However, from the perspective of the accessibility of innovative drugs, the average time for national use of innovative drugs is 6-7 years later than that of developed countries, which is the average time for imported drugs to enter China, while the time for independent research and development of drugs in China will be longer The industry said, "over the years, we have seen the improvement of drug clinical evaluation research and ability, but at the same time, we do have many weak links, mainly the improvement of ability At present, the cost of new drug research and development is high and the time is long, which requires a lot of human and material resources Experts believe that artificial intelligence technology is expected to provide assistance in the research and development of new drugs "Artificial intelligence is expected to help the pharmaceutical industry achieve revolutionary progress, such as diagnosis, detection and other aspects, but also greatly shorten the time people search for small molecules of drugs, improve the efficiency of new drug research and development."